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Background: Gallbladder toxicity, including cholecystitis, has been reported with motesanib, an orally administered
small-molecule antagonist of VEGFRs 1, 2 and 3; PDGFR; and Kit. We assessed effects of motesanib on gallbladder
size and function.
Methods: Patients with advanced metastatic solid tumors ineligible for or progressing on standard-of-care
therapies with no history of cholecystitis or biliary disease were randomized 2:1:1 to receive motesanib 125 mg
once daily (Arm A); 75 mg twice daily (BID), 14-days-on/7-days-off (Arm B); or 75 mg BID, 5-days-on/2-days-off
(Arm C). Primary endpoints were mean change from baseline in gallbladder size (volume by ultrasound;
independent review) and function (ejection fraction by CCK-HIDA; investigator assessment).
Results: Forty-nine patients received ≥1 dose of motesanib (Arms A/B/C, n = 25/12/12). Across all patients,
gallbladder volume increased by a mean 22.2 cc (from 38.6 cc at baseline) and ejection fraction decreased by a
mean 19.2% (from 61.3% at baseline) during treatment. Changes were similar across arms and appeared reversible
after treatment discontinuation. Three patients had cholecystitis (grades 1, 2, 3, n = 1 each) that resolved after
treatment discontinuation, one patient developed grade 3 acute cholecystitis requiring cholecystectomy, and two
patients had other notable grade 1 gallbladder disorders (gallbladder wall thickening, gallbladder dysfunction) (all in
Arm A). Two patients developed de novo gallstones during treatment. Twelve patients had right upper quadrant
pain (Arms A/B/C, n = 8/1/3). The incidence of biliary “sludge” in Arms A/B/C was 39%/36%/27%.
Conclusions: Motesanib treatment was associated with increased gallbladder volume, decreased ejection fraction,
biliary sludge, gallstone formation, and infrequent cholecystitis.
Trial registration: ClinicalTrials.gov NCT00448786Background
A key goal of early-phase studies of investigational can-
cer therapeutics is an assessment of the treatment’s tox-
icity [1]. However, such studies may be poorly powered
to assess the incidence of uncommon adverse events
(AEs) [2], which may be complicated further by incon-
sistent reporting practices [3,4]. Because infrequent AEs* Correspondence: LRosen@mednet.ucla.edu
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reproduction in any medium, provided the ormay be inadequately characterized or overlooked in
early-phase studies, their relationship to treatment dose
and/or schedule can remain undetermined.
Cholecystitis [5-10] and other gallbladder toxicities (in-
cluding biliary colic, cholelithiasis, gallbladder enlarge-
ment, and gallbladder wall thickening/edema [7,8,11,12])
have been reported in clinical trials investigating
motesanib, an orally administered small-molecule antag-
onist of vascular endothelial growth factor receptors
(VEGFRs) 1, 2, and 3; platelet-derived growth factor
(PDGFR); and Kit for the treatment of advanced solidtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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AE in other studies of motesanib as monotherapy [12,13]
or combined with cytotoxic chemotherapy [14] or other
agents [11,15,16]. However, it is unknown how many
patients who received motesanib in these studies had un-
detected or underreported gallbladder toxicity, particularly
given that abdominal pain was a frequently reported AE
[5-8]. Thus, the proportion of patients with changes in
gallbladder size and/or function is potentially greater than
the incidence of gallbladder AEs. The etiology of gallblad-
der toxicity associated with motesanib treatment is uncer-
tain, but it is interesting to note that cholecystitis has been
reported among patients treated with other inhibitors of
tyrosine kinases [17-26].
The previous clinical studies of motesanib suggested that
a dosing regimen of 75 mg twice daily continuously may be
associated with an increased risk of gallbladder toxicities.
Therefore, to investigate more thoroughly the occurrence of
gallbladder toxicity associated with motesanib treatment, we
designed a randomized phase 1b study with three alternative
motesanib dosing regimens to directly assess the effects of
motesanib on both the size and function of the gallbladder
using ultrasound and hepatobiliary iminodiacetic acid scan
using cholecystokinin (CCK-HIDA), respectively.
Methods
Eligibility
Patients (≥18 years) had histologically confirmed advanced
metastatic solid tumors; measurable or nonmeasurable dis-
ease per Response Evaluation Criteria in Solid Tumors
(RECIST) [27] version 1.0; an Eastern Cooperative Oncology
Group performance status ≤2; an in situ gallbladder at
screening ultrasound; adequate cardiac, renal, hepatic, and
hematologic function; and were ineligible to receive or had
progressed on standard-of-care therapies. Key exclusion cri-
teria were history of cholecystitis, prior biliary procedure, or
prior or ongoing biliary disease; uncontrolled central
nervous system metastases; uncontrolled hypertension
(>150/90 mmHg); peripheral neuropathy grade >1; arterial/
venous thrombosis within 1 year and bleeding diathesis or
bleeding within 14 days and major or minor surgery within
28 days or 7 days, respectively, of randomization; radiation
therapy within 14 days; active dosing with anticoagulation
therapy (except prophylactic low-dose warfarin; heparin or
heparin flushes); or prior treatment with small-molecule
VEGFR inhibitors. Prior treatment with bevacizumab was
permitted if the last dose was administered ≥42 days from
randomization. Patients provided written informed con-
sent. Study procedures were approved by an institutional
review board at each site.
Study design and treatment
In this open-label phase 1b study (11 sites in the United
States and Australia), patients were randomized 2:1:1 toreceive (in 21-day cycles) motesanib orally as follows:
125 mg once daily (QD; Arm A), 75 mg twice daily
(BID) for 2 weeks followed by a 1-week treatment-free
period (Arm B), or 75 mg BID for 5 days followed by a
2-day treatment-free period (Arm C). It was hypothe-
sized that the treatment-free periods would prevent
chronic inhibition of the VEGF axis, thus limiting ad-
verse events that may otherwise be associated with con-
tinuous dosing. In each arm, up to eight additional
patients (nonrandomly assigned) could be treated de-
pending on the degree of variability in the primary end-
point measurements. Treatment continued until disease
progression or unacceptable toxicity. Motesanib doses
could be reduced (in 25-mg decrements) or withheld to
manage toxicity; treatment could be resumed at the
lower dose once toxicity had resolved (dose re-escalation
was not permitted). Treatment was discontinued in pa-
tients requiring >2 dose reductions. Hypertension,
thrombosis, gallbladder toxicity, and proteinuria were
managed using protocol-specific guidelines.
The primary endpoints were mean change from
baseline in gallbladder size (volume by ultrasound)
and function (ejection fraction by CCK-HIDA). Sec-
ondary endpoints included mean change from base-
line in gallbladder size (volume) by computed
tomography (CT) scan, maximum change from base-
line in gallbladder size (volume) and function (ejec-
tion fraction), changes in gallbladder dimensions
other than volume (by ultrasound), assessment of
gallbladder filling (by CCK-HIDA), change in gallblad-
der size and function between the last on-treatment
and the last available off-treatment measurement, ob-
jective response, pharmacokinetics of motesanib, and
incidence of treatment-emergent AEs.Assessment of gallbladder size and function
Gallbladder volume was assessed by ultrasound after
a ≥8 hours fast at screening (within 21 days prior to
randomization) and before the motesanib morning dose
on days 8 and 15 of cycle 1, on day 1 of cycles 2 and 3,
every 6 weeks thereafter, and at the safety follow-up (30
to 33 days after the last dose). Ultrasound was
performed weekly when motesanib was withheld and
weekly for 4 weeks following treatment discontinuation.
Gallbladder ultrasound measurements were assessed by
independent central radiologic review (MedQIA, Los
Angeles, CA, USA). Gallbladder ejection fraction was
assessed by investigators or other study site personnel using
CCK-HIDA at screening (within 21 days of randomization),
on day 1 of cycle 2, day 1 of cycle 6 (±3 days), and at
the safety follow-up. Study-specific training and standard
operating procedures were supplied to all radiology
technicians.
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Tumor response per RECIST [27] was assessed by the
investigators. Magnetic resonance imaging or CT scans
were performed at screening, every 6 weeks thereafter,
and at the safety follow-up. Complete or partial re-
sponses were confirmed >28 days after the initial re-
sponse assessment throughout the study. Patients who
discontinued without a postbaseline tumor assessment
or confirmation were considered nonresponders.
Adverse events
AEs occurring during treatment and through the safety
follow-up were recorded and graded according to the
National Cancer Institute Common Terminology Cri-
teria for Adverse Events (version 3.0).
Pharmacokinetic analysis
Blood samples were collected as follows: predose and at
30 minutes and 1, 2, 4, 6, 8, and 24 hours postdose on day
1 of weeks 1 and 4, and predose and 1 to 2 hours postdose
at weeks 2, 3, and 7 and every 3 weeks thereafter.
Noncompartmental analysis was performed on individual
plasma motesanib concentrations from week 1 (day 1 of
cycle 1) and week 4 (day 1 of cycle 2) using validated
WinNonlin Enterprise software (Version 5.1.1, Pharsight
Corporation, Mountain View, CA, USA) to estimate the
maximum observed plasma concentration (Cmax), the ob-
served minimum (trough) plasma concentration at 24
hours postdose (Cmin), and the area under the plasma
concentration-time curve (AUC). Motesanib concentra-
tions were assessed as described previously [14].
Statistical analysis
The sample size was 48 patients. Assuming a standard devi-
ation of 110cc and a one-sided 95% confidence interval (CI),
a sample size of 24 patients for Arm A and 12 patients each
for Arms B and C would allow for an estimate of the overall
average change from baseline in gallbladder volume to
within ±37cc and ±52cc, respectively. Patients were random-
ized 2:1:1.
The ultrasound and CCK-HIDA gallbladder analysis
sets, which included all randomized patients who received
≥1 dose of motesanib and had baseline and ≥1 evaluable
follow-up ultrasound or CCK-HIDA, respectively, were used
for the principal analysis of endpoints related to gallbladder
size and characteristics. For each dosing scheme, estimates
for the mean and maximum change from baseline in gall-
bladder size (volume as measured by ultrasound) and func-
tion (ejection fraction as measured by CCK-HIDA scan)
were calculated. Mean change from baseline was calculated
by taking the difference between the baseline gallbladder
measurement and the average gallbladder measurement ob-
served during study treatment. The mean (95% CI) differ-
ence was then calculated across all patients for eachtreatment arm, and for the whole study population. Max-
imum change from baseline in gallbladder size or volume
was calculated by taking the difference between the baseline
gallbladder measurement and the maximum gallbladder
measurement observed during study treatment. The mean
(95% CI) maximum change from baseline was then calcu-
lated across all patients for each treatment arm, and for the
whole study population. Reversibility of changes in gallblad-
der volume and ejection fraction were evaluated calculating
changes between the last on-treatment measurement and
the last available measurement following the discontinuation
of motesanib. Covariates (treatment, age, sex, body mass
index, and nonsteroidal anti-inflammatory drug [NSAID]
use) were explored in a linear regression model for potential
relationships with gallbladder volume. Objective response
was assessed for the safety analysis set, including only pa-
tients with measureable disease at baseline.
Results
Patients
Between March 20, 2007, and December 12, 2008, 48 patients
were randomized to treatment with motesanib at
three different doses: Arm A (125 mg QD), n = 24;
Arm B (75 mg BID 2 weeks on/1 week off ), n = 12;
Arm C (75 mg BID 5 days on/2 days off), n = 12 (Figure 1).
As permitted per protocol, one additional patient was
nonrandomly assigned to Arm A for a total enrollment of
49 patients; all received ≥1 dose of motesanib. Thyroid
cancer was the most common tumor type (Table 1).
Demographics and baseline characteristics were generally
balanced among the treatment arms, although fewer pa-
tients received prior therapies in Arm A than in Arms B
and C (Table 1). The ultrasound gallbladder analysis set in-
cluded 92% of patients; the CCK-HIDA gallbladder ana-
lysis set included 84% of patients. One patient (Arm A)
with mesothelioma had a cholecystectomy during the
study (see Adverse Events) but had baseline and evaluable
postbaseline assessments and was therefore included in
both gallbladder analysis sets. All patients discontinued
treatment (Figure 1). Twenty patients (80%) in Arm A,
8 (67%) in Arm B, and 8 (67%) in Arm C completed the
safety follow-up. Reasons for not completing the safety
follow-up were disease progression (Arms A and C, n = 1
each), death (Arm A, n = 2; both due to disease progres-
sion), AE (Arm C, n = 1), and withdrawn consent (Arm B,
n = 1). Median follow-up times in Arms A, B, and C were
17 (range, 6–57), 18 (1–58), and 22 (5–60) weeks,
respectively.
Effects of motesanib dose on gallbladder size and
function
Baseline gallbladder volume and ejection fraction were
similar across arms (Table 2). Across all patients, gall-




Arm A: motesanib 125 mg QD (n=25*)
Received motesanib (n=25)
Arm B: motesanib 75 mg BID, 14 d on/7 d off 
(n=12)
Received motesanib (n=12)















Continuing treatment in rollover study† (n=2)
Consent withdrawn (n=1)
Gallbladder analysis set, ultrasound (n=23)
Excluded (n=2)
Gallbladder analysis set, CCK-HIDA (n=22)
Excluded (n=3)
Safety analysis set (n=25)
Gallbladder analysis set, ultrasound (n=11)
Excluded (n=1)
Gallbladder analysis set, CCK-HIDA (n=10)
Excluded (n=2)
Safety analysis set (n=12)
Gallbladder analysis set, ultrasound (n=11)
Excluded (n=1)
Gallbladder analysis set, CCK-HIDA (n=10)
Excluded (n=2)
Safety analysis set (n=12)
Figure 1 Disposition of patients in the study. *One patient was nonrandomly assigned to Arm A and received treatment with motesanib
125 mg QD. †Total shown does not reflect 2 additional patients who discontinued motesanib for other reasons but later were granted a waiver
to continue in a rollover study.
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during motesanib treatment. Gallbladder volume in-
creased from baseline in all dosing cohorts, starting be-
fore the end of the first 21-day motesanib treatment
cycle (Table 2; Figure 2A, B, C).
Motesanib treatment also affected gallbladder func-
tion. Across all patients, ejection fraction decreased by a
mean 19.2% (median, −18.0%; range, −81% to 67%) from
61.3% at baseline during the study. Gallbladder ejection
fraction during treatment was generally lower than base-
line measurements (Table 2; Figure 2D, E, F).
Changes in gallbladder volume and function appeared
to be at least partially reversible. Among 45 patients in
the gallbladder volume analysis set, 33 had an evaluable
ultrasound after motesanib discontinuation. In each arm,
mean changes from last on-treatment to last available
off-treatment measurement indicated a decrease in gall-
bladder volume (Table 2). Similarly, among the 41 pa-
tients in the gallbladder ejection fraction analysis set
who had an evaluable CCK-HIDA after motesanib dis-
continuation (n = 10), gallbladder mean ejection fraction
increased between these two time points (Table 2).
To adjust for potential confounding factors, linear re-
gression analyses were performed. The results were con-
sistent with the data from the preplanned analysis,
showing a trend toward decreasing gallbladder volume
and increasing gallbladder ejection fraction over time
(data not shown).
Treatment, age, sex, body mass index, and NSAID use
were examined in a linear regression model as potentialcovariates for gallbladder volume. Of those, only NSAID
use was positively associated with increased gallbladder
volume as assessed by ultrasound (P = .0133); the other
covariates were not significantly associated with gallblad-
der volume. Exploratory analyses did not show an asso-
ciation between pharmacokinetic exposure to motesanib
and gallbladder volume (data not shown). Covariate ana-
lyses and exploratory pharmacokinetic exposure analyses
for gallbladder ejection fraction could not be performed
because of insufficient ejection fraction data.
Changes in other gallbladder characteristics
Some patients in Arms A and B developed gallstones
and/or pericholecystic fluid while receiving motesanib
(Table 3), including two patients who developed de novo
gallstones; however, two patients with gallstones at base-
line did not have gallstones at subsequent examinations.
Sludge occurred in all three treatment arms at relatively
high incidence rates (Arms A/B/C, 39%/36%/27%).
Adverse events
Adverse events considered related to treatment with
motesanib by investigators were generally consistent in
frequency and severity with what has been reported in
previous motesanib studies [5,7-9,12,14,15]. Incidence of
grade ≥3 treatment-related AEs in Arms A, B, and C
was 32%, 42%, and 33%, respectively. Two patients had
grade 4 AEs (one each in Arms B and C). Two deaths
occurred during the study; both were caused by disease
progression.
Table 1 Patient demographics and baseline characteristics
Characteristics Arm A Arm B Arm C All
patientsMotesanib Motesanib Motesanib
125 mg QD 75 mg BID 2 wk on/1 wk off 75 mg BID 5 d on/2 d off
n = 25 n = 12 n = 12 N = 49
Sex, n (%)
Women 10 (40) 6 (50) 5 (42) 21 (43)
Men 15 (60) 6 (50) 7 (58) 28 (57)
Race, n (%)
White 22 (88) 11 (92) 11 (92) 44 (90)
Black 2 (8) 0 (0) 0 (0) 2 (4)
Hispanic 1 (4) 1 (8) 0 (0) 2 (4)
Native Hawaiian or other Pacific Islander 0 (0) 0 (0) 1 (8) 1 (2)
Median age (range), y 59 (28–70) 52 (30–70) 59 (22–81) 58 (22–81)
Age group, n (%)
<65 y 18 (72) 10 (83) 9 (75) 37 (76)
≥65 y 7 (28) 2 (17) 3 (25) 12 (24)
≥75 y 0 (0) 0 (0) 1 (8) 1 (2)
Tumor type, n (%)
Thyroid 1 (4) 7 (58) 4 (33) 12 (24)
Colon 3 (12) 0 (0) 1 (8) 4 (8)
Non–small-cell lung 3 (12) 0 (0) 1 (8) 4 (8)
Carcinoma of unknown origin 1 (4) 1 (8) 0 (0) 2 (4)
Cervix 1 (4) 0 (0) 1 (8) 2 (4)
Oral 1 (4) 0 (0) 1 (8) 2 (4)
Ovarian 1 (4) 0 (0) 1 (8) 2 (4)
Small-cell lung 0 (0) 2 (17) 0 (0) 2 (4)
Soft tissue sarcoma 1 (4) 0 (0) 1 (8) 2 (4)
Bile duct 1 (4) 0 (0) 0 (0) 1 (2)
Bone sarcoma 1 (4) 0 (0) 0 (0) 1 (2)
Esophageal 1 (4) 0 (0) 0 (0) 1 (2)
Kidney 1 (4) 0 (0) 0 (0) 1 (2)
Liver 1 (4) 0 (0) 0 (0) 1 (2)
Squamous cell carcinoma of head and neck 1 (4) 0 (0) 0 (0) 1 (2)
Other 7 (28) 2 (17) 2 (17) 11 (22)
ECOG performance status, n (%)
0 14 (56) 8 (67) 9 (75) 31 (63)
1 10 (40) 4 (33) 3 (25) 17 (35)
2 1 (4) 0 (0) 0 (0) 1 (2)
Disease stage, n (%)
Stage III 1 (4) 0 (0) 0 (0) 1 (2)
Stage IV 22 (88) 11 (92) 11 (92) 44 (90)
Unknown 2 (8) 1 (8) 1 (8) 4 (8)
Number of sites of disease,* n (%)
0 1 (4) 0 (0) 1 (8) 2 (4)
1 13 (52) 4 (33) 3 (25) 20 (41)
2 10 (40) 5 (42) 6 (50) 21 (43)
≥3 1 (4) 3 (25) 2 (17) 6 (50)
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Table 1 Patient demographics and baseline characteristics (Continued)
Number of prior therapies,† n (%)
0 5 (20) 1 (8) 1 (8) 7 (14)
1 5 (20) 1 (8) 2 (17) 8 (16)
2 2 (8) 1 (8) 3 (25) 6 (12)
≥3 13 (52) 9 (75) 6 (50) 28 (57)
Alcohol use, n (%)
Never 1 (4) 5 (42) 4 (33) 10 (20)
Former 5 (20) 1 (8) 2 (17) 8 (16)
Current 18 (72) 5 (42) 5 (42) 28 (57)
Missing 1 (4) 1 (8) 1 (8) 3 (6)
BID = twice daily; ECOG = Eastern Cooperative Oncology Group; QD = once daily.
*Sites of disease as assessed by investigator.
†Prior therapies include all cancer therapies before study enrollment.
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related) occurred only in Arm A (n = 6, 12%). Three pa-
tients had cholecystitis that resolved after motesanib
treatment was permanently discontinued. One event was
of grade 1 and resolved within 1 week while motesanib
was withheld. One event was of grade 2 and occurred
approximately 1 month after the last motesanib dose; it
resolved 2 months later. A 70-year-old white man with
metastatic non–small-cell lung cancer developed grade
3 cholecystitis that was managed without surgery.Table 2 Gallbladder Volume (per Independent Review) and E
Endpoint
Gallbladder volume, cc (95% CI)
Baseline
Mean change from baseline
Maximum change from baseline
Gallbladder ejection fraction, % (95% CI)
Baseline
Mean change from baseline
Maximum change from baseline
Reversibility of gallbladder volume changes, cc (95% CI)
Mean change in gallbladder volume after discontinuation of motesanib
Mean change in gallbladder volume from baseline to last available
off- treatment measurement
Reversibility of gallbladder ejection fraction changes, % (95% CI)
Mean change in ejection fraction after discontinuation of motesanib
Mean change in ejection fraction from baseline to last available
off- treatment measurement
BID = twice daily; QD = once daily.Symptoms appeared approximately 3 weeks after initi-
ation of motesanib, with ultrasound showing gallbladder
distension and the presence of sludge. CCK-HIDA re-
vealed a patent cystic duct and gallbladder dyskinesia.
The patient discontinued motesanib and was treated
with oxycodone and paracetamol. Three weeks later,
CCK-HIDA measurements were normal and the symp-
toms had resolved. One patient, a 56-year-old white man
with stage IV mesothelioma, had serious grade 3 acute
cholecystitis resulting in cholecystectomy. The eventjection Fraction (per Investigator)
Arm A Arm B Arm C
Motesanib Motesanib Motesanib
125 mg QD 75 mg BID 2 wk on/
1 wk off
75 mg BID 5 d on/
2 d off
n = 23 n = 11 n = 11
n = 23 n = 11 n = 11
33.3 (22.5–44.1) 48.1 (23.1–73.1) 40.2 (14.1–66.2)
17.7 (6.4–28.9) 26.8 (11.5–42.1) 26.9 (8.8–45.1)
45.6 (20.2–70.9) 74.4 (41.3–107.4) 67.3 (30.8–103.8)
n = 21 n = 10 n = 10
59.1 (43.5–74.8) 68.7 (50.5–87.0) 58.5 (38.4–78.6)
−24.1 (−38.2 to −9.9) −25.0 (−43.9 to −6.1) −3.3 (−25.0 to 18.4)
−30.1 (−46.4 to −13.7) −26.5 (−45.0 to −8.0) −6.5 (−29.8 to 16.8)
n = 16 n = 9 n = 8
−8.5 (−38.8 to 21.7) −16.2 (−37.4 to 5.1) −7.4 (−67.1 to 52.4)
10.4 (−10.0 to 30.8) −14.4 (−31.1 to 2.4) 7.1 (−28.9 to 43.0)
n = 5 n = 3 n = 2
10.8 (−45.8 to 67.4) 63.0 (24.0 to 102.0) 46.0 (−347.9 to 439.9)

















































































































































































































Figure 2 Change in gallbladder size and function. Mean (dots connected by lines) and median (25th and 75th quartiles; solid horizontal lines) gallbladder size (A, B, C) and function (D, E, F)

















Table 3 Specific gallbladder findings (per Independent Ultrasound Review)
Arm A Arm B Arm C
Motesanib 125 mg QD Motesanib 75 mg BID Motesanib 75 mg BID















(n = 23) (n = 23) (n = 16) (n = 11) (n = 11) (n = 9) (n = 11) (n = 11) (n = 8)
Gallstones 3 (13) 4 (17) 3 (19) 3 (27) 2 (18) 2 (22) 0 (0) 0 (0) 0 (0)
Sludge 0 (0) 9 (39) 4 (25) 0 (0) 4 (36) 4 (44) 0 (0) 3 (27) 0 (0)
Pericholecystic fluid 0 (0) 1 (4) 0 (0) 1 (9) 1 (9) 0 (0) 0 (0) 0 (0) 0 (0)
Common duct
dilation
0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
*Data within the table indicate number of patients with at least one incidence of the specific gallbladder findings listed at any point during
postbaseline treatment.
†Data within the table indicate number of patients who had the specific gallbladder findings listed at their last available off-treatment assessment.
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ation. At the time of hospitalization, the patient had a
24-hour history of right upper quadrant pain; Murphy’s sign
was positive on abdominal examination. Motesanib was
withheld, and ultrasound revealed gallbladder distension,
wall thickening (4.4 cm), intramural edema, mural
hypervascularity, trace of pericholecystic fluid, and no biliary
tract dilation. Cholecystectomy was performed 8 days after
cessation of motesanib, and the patient resumed motesanib
treatment 11 days later. At the safety follow-up, two patients
had ongoing grade 1 gallbladder disorders, specifically gall-
bladder dysfunction and gallbladder wall thickening, with
the latter prompting a dose reduction. Twelve patients had
right upper quadrant pain during the study (Arms A/B/C,
n = 8/1/3); these events occurred at variable times after initi-
ation of motesanib. However, the available data do not helpTable 4 Gallbladder-related toxicity and potential gallbladde
other than motesanib
Agent Molecular target(s) Study / Study typ
Cediranib VEGFR1, VEGFR2, VEGFR3 Laurie et al. [21] – phase
Batchelor et al. [22] – p
study
Imatinib BCR-ABL, Kit, PDGFR-α, PDGFR-β Yeh et al. [23] – single-ar
Breccia et al. [37] – case
Grant et al. [24] – phase
Sorafenib VEGFR1, VEGFR2, VEGFR3, Raf,
PDGFR-β, Flt-3, Kit





Sunitinib VEGFR1, VEGFR2, VEGFR3, PDGFR-α,
PDGFR-β, Flt-3, Kit
Motzer et al. [17] – sing
study
De Lima Lopes, Jr., et a
case report
Gomez-Abuin et al. [19]
report
ALT = alkaline phosphatase; PDGFR = platelet-derived growth factor receptor; VEGFRdistinguish between pain due to gallbladder toxicity versus
other etiologies, such as liver metastases.
Objective response
Most patients had measureable disease at baseline (Arm A,
n = 24 [96%]; Arm B, n = 12 [100%]; Arm C, n = 11 [92%]).
No complete responses were achieved, but one patient with
stage IV thyroid cancer in Arm B had a confirmed partial
response (overall objective response rate, 2%). Twenty-eight
patients (60%) had stable disease as best tumor response
(Arm A, n = 15 [63%]; Arm B, n = 6 [50%]; Arm C, n = 7
[64%]), with durable (≥24 weeks) stable disease in 8 (17%)
patients (Arm A, n = 6 [25%]; Arm B, n = 1 [8%]; Arm C,
n = 1 [9%]). Fifteen patients (32%) had progressive dis-
ease (Arm A, n = 8 [33%]; Arm B, n = 3 [25%]; Arm C,
n = 4 [36%]).r-related toxicity reported with tyrosine kinase inhibitors
e Adverse events reported
1 study Acute cholecystitis
hase 2 Gallbladder obstruction, abdominal pain
m study Gallstones
report Gallstones, gallbladder wall thickening, abdominal pain
1 study Cholecystitis







l. [18] – Acute emphysematous cholecystitis, right upper abdominal
pain, gallbladder distension
– case Acute acalculous cholecystitis, right upper abdominal pain,
gallbladder wall thickening
= vascular endothelial growth factor receptor.
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Motesanib was rapidly absorbed, and there was no evi-
dence of drug accumulation after QD administration.
The median Cmax values in Arms A, B, and C were 630,
323, and 355 ng/mL, respectively; the median Cmin values
were 14, 60, and 35 ng/mL, respectively. In Arm B, the
median motesanib concentration after the 1-week wash-
out period was <0.2 ng/mL (the limit of quantitation); in
Arm C, the median motesanib concentration after the
2-day wash-out period was 1.2 ng/mL. The median AUC
values estimated from the three dosing regimens ap-
peared similar, ranging from 1.9 to 3.0 μg·hr/mL.
An exploratory analysis investigated the potential rela-
tionship between drug exposure (Cmax, Cmin, and AUC) and
change in gallbladder size. The results showed no consistent
trend between gallbladder size and motesanib exposure.Discussion
In this randomized phase 1b study designed to assess
gallbladder-related toxicity among patients receiving
three motesanib dose schedules, increased gallbladder
volume, decreased gallbladder function, and other
gallbladder changes, including development of gall-
stones and sludge, were common. Changes in gall-
bladder volume were observed as early as in the first
cycle of motesanib treatment. Symptomatic gallbladder
toxicity occurred in six patients, one of whom had acute
cholecystitis requiring a cholecystectomy. Other toxicities
were generally consistent with those reported in previous
motesanib studies and for the class of VEGF pathway in-
hibitors. While increases in gallbladder volume and de-
creases in gallbladder function did not appear to be dose-
or schedule-dependent, gallbladder toxicity occurred only
in Arm A (motesanib 125 mg QD).
Gallbladder toxicity, at varying incidence rates, has been
described in most motesanib studies [5,7,8,10,28]; how-
ever, considering the findings summarized herein,
gallbladder-associated AEs may have been underdetected.
This may particularly apply to earlier-conducted studies
that reported no [12-16] or low [5,9,28] incidence rates of
cholecystitis (but no other gallbladder toxicity) and to pa-
tients who presented only with right upper quadrant pain
along with other possible reasons for pain, including liver
metastases. For example, Sawaki and colleagues described
the incidental discovery by ultrasound of extended gall-
bladder or wall thickening in three patients [12]. Given
that many VEGF pathway inhibitors block the same or simi-
lar targets as motesanib (Table 4), and because of the inci-
dence of abdominal pain with tyrosine kinase inhibitors
[17-26,29-37], changes in gallbladder size and function not
manifested as symptomatic toxicity may occur more fre-
quently during treatment with these agents than generally
believed. The results of our study should encourageinvestigators to more closely examine potentially gallbladder-
related symptoms in studies of VEGF pathway inhibitors and
among patients treated outside of clinical trials.
The biologic mechanisms that underlie the gallbladder
changes associated with motesanib treatment are not yet
elucidated. The toxicity may be related to antiangiogenic ac-
tivity of motesanib in the gallbladder which could be exacer-
bated by accumulated motesanib, considering the drug’s
biliary excretion pattern (Amgen Inc., data on file). Accu-
mulation of motesanib within the gallbladder following the
excretion (and reactivation) of its major metabolite,
motesanib glucuronic acid [38], in the relatively high pH of
the bile may result in irritation to the gallbladder or possibly
even transient ischemia with subsequent sludge accumula-
tion, transient obstruction, pain, and ultimately, cholecystitis
or cholecystitis-like symptoms. One potential solution may
be to avoid conditions that are known to reduce gallbladder
emptying such as fasting and low-fat diets. Consideration
should also be given to the possibility that gallbladder tox-
icity is an on-target effect of inhibition of one or more of
the molecular targets of tyrosine kinase inhibitors.
The design of this study may be appropriate for investi-
gating gallbladder toxicity with other investigational agents,
including tyrosine kinase inhibitors. The measured changes
from baseline in gallbladder volume and ejection appeared
to be both robust and greater than anticipated inter- or
intrapatient variance. In Arms A and B, the 95% Cl for the
mean and maximum changes from baseline did not en-
compass zero, and the observed changes were consistent
with differences between patients with gallbladder disease
and healthy control participants reported in previous stu-
dies [39,40]. Thus, the results demonstrate that, when
coupled with rigorous quality control/assurance procedures
and training, routine diagnostic techniques (eg, ultrasound,
CT, and CCK-HIDA [41]) can be used to evaluate the inci-
dence and timing of gallbladder toxicity assessed as changes
in volume, ejection fraction, and filling, and to identify
other abnormalities, such as gallstones and pericholecystic
fluid. Better characterization of these risks is important be-
cause of the potential seriousness of gallbladder toxicity.
More broadly, targeted assessments of specific AEs may
help characterize the toxicity of investigational cancer ther-
apeutics. The study was limited by the lack of a placebo
arm, and the small sample size potentially restricted AE
and other assessments.
Conclusions
In conclusion, motesanib monotherapy was associated with
increased gallbladder volume and decreased ejection frac-
tion in most patients, regardless of dosing regimen and ex-
posure, which appeared to be at least partially reversible.
Motesanib had a toxicity profile consistent with previous
studies. The etiology of gallbladder toxicity during
motesanib treatment remains uncertain.
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